Additional company information can be found at http://www.plcmed.com.
This press release contains "forward-looking" statements. For this
purpose, any statements contained in this press release that relate to
prospective events or developments are deemed to be forward-looking
statements. Words such as "believes," "anticipates," "plans," "expects,"
"will" and similar expressions are intended to identify forward-looking
statements. While we may elect to update forward-looking statements in the
future, we specifically disclaim any obligation to do so, even if our
estimates change, and you should not rely on these forward-looking
statements as representing our views as of any date subsequent to the date
of this press release. Actual results could differ materially from those
indicated by such forward-looking statements as a result of a variety of
important factors, including that we may not receive necessary regulatory
approvals to market our RenalGuard product or that such approvals may be
withdrawn, we may be unable to raise sufficient funds in the future to
implement our business plan and/or commence our planned U.S. clinical trial
for RenalGuard, the current CCM clinical trial and the planned future U.S.
clinical trial for RenalGuard as a safe and effective CIN prevention device
may not be completed in a timely fashion if at all, or, if these clinical
trials are completed, they may not
|SOURCE PLC Systems Inc.|
Copyright©2008 PR Newswire.
All rights reserved